Lupin to Acquire Two Inhalation Brands from Sunovion

#SunovionPharmaceuticals #Lupin #InhalationMedicines

Source: Lupin

“The addition of these two brands enhances our position in the segment.” - Vinita Gupta, CEO, Lupin

November 2022: Global pharmaceutical major Lupin Limited (Lupin) has recently announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. (Sunovion) for a purchase price of US$ 75 million. Lupin expects the transaction to be accretive to earnings in the first year.

The acquisition of these two brands expands Lupin’s portfolio of inhalation products in the US and strengthens the company’s presence in the respiratory therapy area while continuing to provide patients access to these important medicines. Vinita Gupta, CEO, Lupin said “We remain focused on strengthening our respiratory franchise in the U.S. We have established a strong position in the respiratory segment with our Albuterol MDI and Brovana authorized generic launch. The addition of these two brands enhances our position in the segment.”